J&J Innovation Launches JLINX To Catalyze Company Formation
This article was originally published in Scrip
Johnson & Johnson Innovation is expanding its innovation strategy to include a new initiative in Europe that combines venture investment and company incubation. The initiative is called JLINX and it is hoped that it will catalyze scientific innovation and successful company formation by offering start-ups flexible ways to grow and collaborate across the European life science ecosystem.
You may also be interested in...
J&J’s Robert Urban explains how his organization’s efforts lead to partnerships with academia across a broad range of areas, including pharmaceuticals, medical devices and consumer products. Also, transactions occurring between Nov. 21 and Dec. 21, including the expansion and solidification of Editas Medicine’s IP estate in CRISPR technology.
Reflecting on the latest batch of deals, Global Head Robert Urban discusses the progress J&J Innovation has made so far and the next steps as it launches its JLINX incubator.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.